Science & Enterprise subscription

Follow us on Twitter

  • As the U.S. enters its Independence Day in the midst of its worst-ever pandemic, a divided public most trusts its h… https://t.co/umw9fDWuvJ
    about 8 hours ago
  • New post on Science and Enterprise: Infographic – Health Agencies Trusted for Covid-19 Info https://t.co/RerieMYQgn #Science #Business
    about 8 hours ago
  • Change the name of the Washington NFL team? A respondent to @joshtpm has a brilliant idea ... Washington Dukes, for… https://t.co/J9P4LKG2PT
    about 22 hours ago
  • A medical software team designed a mobile app that records and analyzes a person's sounds and sleep positions to de… https://t.co/NB99HQUWpC
    about 1 day ago
  • New post on Science and Enterprise: Mobile App Screens for Sleep Apnea https://t.co/N8gTn2zWhe #Science #Business
    about 1 day ago

Please share Science & Enterprise

Peanut Allergy Therapy Company Raises $160 Million in IPO

(National Institute of Food and Agriculture, USDA)

6 August 2015. Aimmune Therapeutics Inc., a developer of treatments for peanut and other food allergies, raised $160 million from its initial public stock offering, pricing its 10 million shares at $16.00. Shares in the Brisbane, California company trade on the Nasdaq exchange under the symbol . . . → Read More: Peanut Allergy Therapy Company Raises $160 Million in IPO

Drug Delivery Biotech Raises $101.8 Million in IPO

(A. Kotok)

17 July 2015. Chiasma Inc., a biotechnology enterprise developing oral therapies to replace injected drugs, raised some $101.8 million in its initial public stock offering. The company — located in Newton, Massachusetts and Jerusalem, Israel — issued 6,365,000 shares at $16.00, and trades on the Nasdaq exchange under the symbol CHMA. . . . → Read More: Drug Delivery Biotech Raises $101.8 Million in IPO

Rare Disease Therapy Company Raises $60 Million in IPO

(bfishadow, WikimediaCommons)

26 June 2015. Catabasis Pharmaceuticals Inc., a biotechnology company creating treatments for rare diseases and cholesterol-related disorders, is raising $60 million in its initial public stock offering, trading on the Nasdaq exchange under the symbol CATB. The Cambridge, Massachusetts enterprise yesterday priced its 5 million shares at $12.00, and as of . . . → Read More: Rare Disease Therapy Company Raises $60 Million in IPO

Life Sciences Commercialization Firm to Crowdfund IPO

(bfishadow, WikimediaCommons)

4 June 2015. Innovation Economy Corporation is going public by skipping the usual route of hiring an investment bank, and instead will use crowdfunding to attract investors to its initial public offering of stock. The Riverside, California enterprise, that goes by the trade name ieCrowd, licenses life science and health-related technologies . . . → Read More: Life Sciences Commercialization Firm to Crowdfund IPO

Cancer Biotech Raising $147 Million in IPO

(A. Kotok)

30 April 2015. Blueprint Medicines, a developer of cancer therapies that block enzymes supporting tumor growth, is raising some $146.7 million in its initial public stock offering. The Cambridge, Massachusetts enterprise, listed on the NASDAQ exchange under the symbol BPMC, issued 8.15 million shares at $18.00.

The company began trading today . . . → Read More: Cancer Biotech Raising $147 Million in IPO

Aduro Biotech Raises $108 million in IPO

Listeria bacteria (CDC.gov)

15 April 2015. Aduro Biotech Inc., a developer of immunotherapies to treat cancer, issued its initial public stock offering today that expects to net the company some $108 million, after issuing 7 million shares priced at $17.00. The Berkeley, California enterprise trades on the Nasdaq exchange under symbol ADRO. As . . . → Read More: Aduro Biotech Raises $108 million in IPO

Immunotherapy Biotech Raising $45 Million in IPO

Herpes simplex viruses (Centers for Disease Control and Prevention)

12 March 2015. Genocea Biosciences Inc., a biotechnology company developing immunotherapies to treat genital herpes and other diseases, is raising $45 million in its initial public offering of stock. The Cambridge, Massachusetts enterprise is issuing 5,454,545 shares priced at $8.25. The company trades on . . . → Read More: Immunotherapy Biotech Raising $45 Million in IPO

Gene Therapy Biotech Raises $161M in IPO

(Michael Daddino/Flickr)

30 January 2015. Spark Therapeutics Inc., a biotechnology company in Philadelphia, is raising $161 million in its initial public stock offering. The company, developing genetic therapies for inherited diseases, priced 7 million shares of its common stock at $23.00 a share. The stock trades on the NASDAQ exchange under the symbol . . . → Read More: Gene Therapy Biotech Raises $161M in IPO

Fertility Science Company Raises $115 Million in IPO

(CDC.gov)

8 January 2015. OvaScience Inc., a developer of fertility treatments using a woman’s early-forming egg cells, issued its initial public offering of common stock, raising some $115 million. The Cambridge, Massachusetts company that trades on the NASDAQ exchange under the symbol OVAS, issued 2.3 million shares yesterday priced at $50.00. At 12 . . . → Read More: Fertility Science Company Raises $115 Million in IPO

Juno Therapeutics Raises $265 Million in IPO

(A. Kotok)

19 December 2014. Juno Therapeutics, a biotechnology company spun-off from research labs in Seattle and New York, raised some $265 million yesterday in its initial public stock offering. The Seattle enterprise developing cancer therapies that harness the immune system issued 11 million shares of common stock priced at $24.00, and trades . . . → Read More: Juno Therapeutics Raises $265 Million in IPO